Open Collections

Description

Therapeutics Letter 102 reviews indacaterol for obstructive pulmonary disease. Conclusions: The only single product dose of inhaled indacaterol approved in Canada is 75 µg. Doses of indacaterol higher than 75 µg were not significantly different in any clinically meaningful outcome measure as compared to lower doses. There are no proven clinically meaningful benefits in terms of reduction in mortality or total serious adverse events for indacaterol in patients with COPD. Because the overall evidence is graded as of very low quality, it is unclear whether indacaterol causes a clinically meaningful reduction in acute exacerbations, improvement in quality of life, dyspnea or reduced need for rescue medications. For any new class of drugs for COPD, evidence of a reduction in clinically relevant outcomes should be required for licensing.